Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients

Azra Raza, MD, Can Yalçın, Miray Cimist, Ryan Shelton, BS, Syed Fazl Ali Bilgrami, MD, Mark Lawrence Heaney, MD PhD, Abdullah Mahmood Ali, PhD

Blood (2017) 130 (Supplement 1): 5316.

https://doi.org/10.1182/blood.V130.Suppl_1.5316.5316

Published: 2017

Journal Articles

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Aaron T. Gerds, MDMS, Tetsuzo Tauchi, MD, Ellen K. Ritchie, MD, Michael W. Deininger, MD PhD, Catriona HM Jamieson, MD PhD, Ruben Mesa, MD FACP, Mark Lawrence Heaney, MD PhD, Norio Komatsu, MD PhD, Hironobu Minami, MD PhD, M. Naveed Shaik, PhD, Xiaoxi Zhang, PhD, Christine DiRienzo, PhD, Mirjana Zeremski, MD, Geoffrey Chan, MD, Moshe Talpaz, MD

Blood (2017) 130 (Supplement 1): 258.

https://doi.org/10.1182/blood.V130.Suppl_1.258.258

Published: 2017

Journal Articles

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Azra Raza, MD, Aref Al-Kali, MD, Raoul Tibes, MD PhD, Gary Spitzer, MD, Manila Gaddh, MD, Benjamin Tycko, MD PhD, Sangmin Lee, MD, Naomi Galili, PhD, Abdullah Mahmood Ali, PhD, John G. Mears, MD, Siddhartha Mukherjee, MD PhD, Ryan Shelton, BS, Steven M. Fruchtman, MD, Michael E. Petrone, MD MPH, Patrick S. Zbyszewski, MBA, Mark Lawrence Heaney, MD PhD

Blood (2017) 130 (Supplement 1): 1689.

https://doi.org/10.1182/blood.V130.Suppl_1.1689.1689

Published: 2017

Journal Articles

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Daniel J. Lee, MD, Todd L. Rosenblat, MD MS, Mark Lawrence Heaney, MD PhD, Joseph G. Jurcic, MD, Azra Raza, MD, Kristina Gazivoda, Katherine Harwood, Ryan Shelton, Hakim Djaballah, PhD, Joseph M. Scandura, MD PhD, Anthony Letai, MD PhD, Mark G. Frattini, MD PhD

Blood (2016) 128 (22): 2816.

https://doi.org/10.1182/blood.V128.22.2816.2816

Published: 2016

Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)

Blood (2016) 128 (22): 1124.

https://doi.org/10.1182/blood.V128.22.1124.1124

Published: 2016

Journal Articles

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Gabriella Hobbs, MD, Rivka Litvin, Jihae Ahn, Anna Sophia Mckenney, Michael J. Mauro, MD, Martin S Tallman, MD, Ellin Berman, MD, Mark Lawrence Heaney, MD PhD, Ross L. Levine, MD, Raajit K. Rampal, MD, PhD

Blood (2015) 126 (23): 4075.

https://doi.org/10.1182/blood.V126.23.4075.4075

Published: 2015

Journal Articles

Soluble GM-CSF Receptor α Is Cytotoxic to Myeloid Cells in a Manner That Is Independent of GM-CSF Binding Inhibition.

Jeffrey R Gardner, BS, MBA, Mark Lawrence Heaney, MD, PhD, Linghao Niu, PhD

Blood (2009) 114 (22): 3618.

https://doi.org/10.1182/blood.V114.22.3618.3618

Published: 2009

Journal Articles

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

Mark G. Frattini, MD, PhD, David Shum, M.S., Kristen M O’Dwyer, M.D., Renier J. Brentjens, MD, PhD, Ray Yeh, Ph.D., Peter Maslak, MD, Mark Lawrence Heaney, MD, PhD, Joseph Jurcic, MD, Hakim Djaballah, Ph.D., Thomas J Kelly, M.D., Ph.D.

Blood (2008) 112 (11): 2668.

https://doi.org/10.1182/blood.V112.11.2668.2668

Published: 2008

Journal Articles

The Novel Human Ph + Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice

Mark G. Frattini, MD, PhD, Elmer Santos, MD, PhD, Mark Lawrence Heaney, MD, PhD, Peter Maslak, MD, Suresh C Jhanwar, PhD, Steven M Larson, MD, Elisa De Stanchina, PhD, Bayard Clarkson, MD, Renier J. Brentjens, MD, PhD

Blood (2008) 112 (11): 4875.

https://doi.org/10.1182/blood.V112.11.4875.4875

Published: 2008

Journal Articles

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Edmond L Toy, PhD, Francis Vekeman, MA, François Laliberté, MA, Bree Dority, PhD, Daniel Perlman, Victoria Barghout, MSPH, Mei Sheng Duh, MPH, ScD, Mark Lawrence Heaney, MD, PhD

Blood (2008) 112 (11): 665.

https://doi.org/10.1182/blood.V112.11.665.665

Published: 2008

NARROW

Long Term Responses to Rigosertib in Lower-Risk Myelodysplastic Syndromes (MDS) Patients

Phase I/II Trial of Glasdegib in Heavily Pre-Treated Patients with Primary or Secondary Myelofibrosis

Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study

Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies

Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)

AUY922, a Heat Shock Protein 90 (Hsp90) Inhibitor, Demonstrates Activity in Patients with Myeloproliferative Neoplasms (MPNs)

Soluble GM-CSF Receptor α Is Cytotoxic to Myeloid Cells in a Manner That Is Independent of GM-CSF Binding Inhibition.

Small Molecule Inhibition of Cdc7, a Key Cell Cycle Regulator and Novel Therapeutic Target, Successfully Inhibits Leukemia Cell Growth in Vitro and in Vivo

The Novel Human Ph + Acute Lymphoblastic Leukemia Cell Line PhALL3.1 Is Amenable to Retroviral Gene Transfer and Mimics Human Disease Progression in SCID-Beige Mice

Comparison of Infection-Related Hospitalization Risk and Associated Costs among Patients Receiving Sargramostim (Leukine®), Filgrastim (Neupogen®), and Pegfilgrastim (Neulasta®) for Chemotherapy-Induced Neutropenia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only